Deutsche Bank Ag\ Nuvation Bio Inc. Call Options Transaction History
Deutsche Bank Ag\
- $240 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NUVB
# of Institutions
158Shares Held
157MCall Options Held
3.2KPut Options Held
98.7K-
Decheng Capital LLC Menlo Park, CA26MShares$73.2 Million14.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA19.2MShares$54.2 Million1.92% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$45.8 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.1MShares$36.9 Million44.61% of portfolio
-
Octagon Capital Advisors LP New York, NY12.2MShares$34.3 Million6.76% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $613M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...